Streetbeat News

Analyst Ratings

GPN

BMO Capital analyst James Fotheringham maintains an 'Outperform' rating on Global Payments (NYSE:GPN) and raises the price target from $208 to $211.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 11:14 am

NVRO

Wells Fargo analyst Lawrence Biegelsen has maintained an Equal-Weight rating on Nevro (NYSE:NVRO) and lowered the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:14 am

NBIX

BMO Capital analyst Evan Seigerman has maintained a 'Market Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $96 to $100.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 11:14 am

FRSH

Baird analyst Rob Oliver maintains an Outperform rating on Freshworks (NASDAQ:FRSH) and raises the price target from $18 to $24.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 11:14 am

ECL

Baird analyst Andrew Wittmann maintains a Neutral rating on Ecolab (NYSE:ECL) and raises the price target from $174 to $200.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 11:14 am

MAR

BMO Capital analyst Ari Klein maintains a Market Perform rating on Marriott Intl (NASDAQ:MAR) and raises the price target from $192 to $210.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 11:14 am

OSK

Oshkosh Corporation (NYSE:OSK) reported better-than-expected Q2 results and issued FY23 guidance. The company's earnings per share and sales both exceeded market estimates. Following the announcement, Oshkosh shares rose 10.1%. Analysts from Keybanc, Raymond James, Goldman Sachs, and Baird have revised their price targets for Oshkosh.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 11:14 am

EA

Baird analyst Colin Sebastian maintains an Outperform rating on Electronic Arts (NASDAQ:EA) and raises the price target from $140 to $146.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 11:14 am

ARES

Wells Fargo analyst Timothy O'Shea has maintained an Equal-Weight rating on Ares Management (NYSE:ARES) and raised the price target from $97 to $107.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:14 am

VRTX

Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $410 to $425.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:14 am